Phase I/II Trial of BMS-986205 and Nivolumab as First or Second Line Therapy in Hepatocellular Carcinoma
Latest Information Update: 05 Dec 2023
At a glance
- Drugs Linrodostat (Primary) ; Nivolumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Dec 2023 Results(n=8) describing the data of dose escalation cohort, published in the Investigational New Drugs
- 19 Aug 2023 Status changed from active, no longer recruiting to discontinued due to funding source decision to terminate study.
- 07 Jun 2022 Results (n=8) of the dose escalation cohort, presented at the 58th Annual Meeting of the American Society of Clinical Oncology